CN111867584A - 作为蛋白质精氨酸甲基转移酶的抑制剂的乙二胺-杂环衍生物 - Google Patents
作为蛋白质精氨酸甲基转移酶的抑制剂的乙二胺-杂环衍生物 Download PDFInfo
- Publication number
- CN111867584A CN111867584A CN201980020505.5A CN201980020505A CN111867584A CN 111867584 A CN111867584 A CN 111867584A CN 201980020505 A CN201980020505 A CN 201980020505A CN 111867584 A CN111867584 A CN 111867584A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- compound
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637147P | 2018-03-01 | 2018-03-01 | |
| US62/637,147 | 2018-03-01 | ||
| PCT/US2019/020395 WO2019169326A1 (en) | 2018-03-01 | 2019-03-01 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111867584A true CN111867584A (zh) | 2020-10-30 |
Family
ID=67767960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980020505.5A Pending CN111867584A (zh) | 2018-03-01 | 2019-03-01 | 作为蛋白质精氨酸甲基转移酶的抑制剂的乙二胺-杂环衍生物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11028083B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3758698A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7305664B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867584A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019226585A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017541A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092579A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019169326A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
| WO2022192527A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) * | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| US20130059845A1 (en) * | 2011-08-26 | 2013-03-07 | Metabolex, Inc. | Bicyclic agonists of gpr131 and uses thereof |
| US20140288124A1 (en) * | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20140315904A1 (en) * | 2013-03-14 | 2014-10-23 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| CN105339351A (zh) * | 2013-03-14 | 2016-02-17 | Epizyme股份有限公司 | 精氨酸甲基转移酶抑制剂及其用途 |
| WO2017145013A1 (en) * | 2016-02-23 | 2017-08-31 | Pfizer Inc. | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004149429A (ja) * | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9133189B2 (en) * | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
| EP3363434A1 (en) * | 2013-03-14 | 2018-08-22 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| EP2970181B1 (en) * | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970135B1 (en) * | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US20170283400A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
| US20170280720A1 (en) * | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
-
2019
- 2019-03-01 BR BR112020017541-2A patent/BR112020017541A2/pt not_active Application Discontinuation
- 2019-03-01 JP JP2020545293A patent/JP7305664B2/ja active Active
- 2019-03-01 WO PCT/US2019/020395 patent/WO2019169326A1/en not_active Ceased
- 2019-03-01 CA CA3092579A patent/CA3092579A1/en active Pending
- 2019-03-01 CN CN201980020505.5A patent/CN111867584A/zh active Pending
- 2019-03-01 US US16/290,675 patent/US11028083B2/en not_active Expired - Fee Related
- 2019-03-01 AU AU2019226585A patent/AU2019226585A1/en not_active Abandoned
- 2019-03-01 EP EP19761558.6A patent/EP3758698A4/en not_active Withdrawn
-
2021
- 2021-05-04 US US17/307,568 patent/US11725008B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) * | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| US20130059845A1 (en) * | 2011-08-26 | 2013-03-07 | Metabolex, Inc. | Bicyclic agonists of gpr131 and uses thereof |
| US20140288124A1 (en) * | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20140315904A1 (en) * | 2013-03-14 | 2014-10-23 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| CN105339351A (zh) * | 2013-03-14 | 2016-02-17 | Epizyme股份有限公司 | 精氨酸甲基转移酶抑制剂及其用途 |
| WO2017145013A1 (en) * | 2016-02-23 | 2017-08-31 | Pfizer Inc. | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017541A2 (pt) | 2020-12-22 |
| EP3758698A1 (en) | 2021-01-06 |
| WO2019169326A1 (en) | 2019-09-06 |
| US11028083B2 (en) | 2021-06-08 |
| JP7305664B2 (ja) | 2023-07-10 |
| US20190270739A1 (en) | 2019-09-05 |
| CA3092579A1 (en) | 2019-09-06 |
| AU2019226585A1 (en) | 2020-10-08 |
| US20230027126A1 (en) | 2023-01-26 |
| EP3758698A4 (en) | 2021-10-20 |
| US11725008B2 (en) | 2023-08-15 |
| JP2021514999A (ja) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019263294B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
| CN115557974A (zh) | Kras g12d抑制剂及其应用 | |
| AU2019245403B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| CN105939997B (zh) | 作为dlk抑制剂的吡唑衍生物及其用途 | |
| WO2023109883A1 (zh) | 一类芳杂环取代的化合物及其制备方法和用途 | |
| WO2021219072A1 (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| WO2019174533A1 (zh) | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 | |
| CN110088096A (zh) | 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物 | |
| CN102388043A (zh) | 组胺h3反相激动剂和拮抗剂及其使用方法 | |
| CN101903384A (zh) | 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物 | |
| TW201605866A (zh) | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 | |
| CN104918934A (zh) | 3-取代的吡唑及其作为dlk抑制剂的用途 | |
| CN115515940A (zh) | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 | |
| JP2019528319A (ja) | 疾患の処置のための二重ロイシンジッパー(dlk)キナーゼの阻害薬 | |
| CN107921044A (zh) | 用于治疗疾病的gls1抑制剂 | |
| TW202417449A (zh) | Cdk2抑制劑及使用彼等之方法 | |
| EP4484420A1 (en) | Inhibitor of interaction between yap/taz and tead, preparation thereof, pharmaceutical composition thereof and use thereof | |
| US11725008B2 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| TW202604527A (zh) | 一種含氮雜環類化合物、其製備方法及其應用 | |
| EP4153601A1 (en) | Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5 | |
| CN120603818A (zh) | Nlrp3抑制剂 | |
| WO2023151635A1 (zh) | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 | |
| WO2022192527A1 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| CN117659023A (zh) | 吡啶乙酰胺类衍生物、包含其的药物组合物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201030 |